Mount Yale Investment Advisors LLC Sells 6,775 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mount Yale Investment Advisors LLC reduced its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 56.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,174 shares of the medical equipment provider's stock after selling 6,775 shares during the quarter. Mount Yale Investment Advisors LLC's holdings in Hologic were worth $373,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in HOLX. Public Sector Pension Investment Board increased its stake in Hologic by 92.5% in the 2nd quarter. Public Sector Pension Investment Board now owns 8,759 shares of the medical equipment provider's stock valued at $650,000 after buying an additional 4,208 shares during the last quarter. Creative Planning boosted its holdings in shares of Hologic by 2.4% in the 2nd quarter. Creative Planning now owns 21,813 shares of the medical equipment provider's stock valued at $1,620,000 after buying an additional 503 shares during the last quarter. Sunbelt Securities Inc. bought a new position in shares of Hologic in the 2nd quarter valued at about $37,000. Quarry LP raised its holdings in shares of Hologic by 323.7% in the 2nd quarter. Quarry LP now owns 1,809 shares of the medical equipment provider's stock valued at $134,000 after purchasing an additional 1,382 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Hologic in the 2nd quarter valued at about $1,212,000. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Shares of Hologic stock traded up $0.76 during trading on Thursday, reaching $72.17. 1,190,776 shares of the company's stock were exchanged, compared to its average volume of 2,380,083. The firm's 50-day moving average price is $73.62 and its 200 day moving average price is $78.16. The company has a market cap of $16.29 billion, a P/E ratio of 21.67, a PEG ratio of 2.43 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 1-year low of $68.61 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts' consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 earnings per share. As a group, research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.88% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. UBS Group raised their price objective on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They issued a "peer perform" rating on the stock. Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Finally, Mizuho decreased their price objective on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.